Document is current
Any future updates will be listed below
-
Authors
Liu, Xiaoli
Yin, Xiaoyan
Zhuang, Lulu
Wen, Junxu
Wei, Zhonghui
Cui, Wenxing
Yu, Minghao
Zhao, Kaikai
Liu, Lanping
Kong, Lingling
Jiang, Liyang
Jing, Xuquan
Zhu, Hui
Wang, Xunqiang
Dong, Xinjun
Yu, Jinming
Meng, Xiangjiao
-
Funding
Funding for this research was provided by:
Chia Tai Tianqing Pharmaceutical Group Co., Ltd
National Natural Science Foundation of China (82272845)
Natural Science Foundation of Shandong Province (ZR2023LZL001)
- License Information
-
More Information
Article History
Received: 15 January 2025
Accepted: 7 March 2025
First Online: 20 March 2025
Declarations
:
: The study was conducted in accordance with the Declaration of Helsinki and received approval from the Ethics Committee of Shandong Cancer Hospital, affiliated with Shandong First Medical University, and secured its registration at the Clinical Trials. All participants provided written informed consent before the study’s commencement.
: The authors declare no competing interests.
